(Reuters) – Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows. Read full story
Capitol Hill drug pricing reform opponents among the biggest beneficiaries of pharma funds
